Skip to content

Clinical study of hyperbaric oxygenation combined with concurrent radiochemotherapy in the postoperative treatment of patients with glioblastoma

Clinical study of hyperbaric oxygenation combined with concurrent radiochemotherapy in the postoperative treatment of patients with glioblastoma

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016330
Enrollment
Unknown
Registered
2018-05-25
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Interventions

treatment groop:hyperbaric oxygenation combined with standard treatment
control group:standard treatment

Sponsors

Tianjin Huanhu Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years old; 2. Diagnosis of glioblastoma by surgical pathology; 3. There is at least one intracranial target lesion defined by the neurotumor response evaluation standard (RANO) ; 4. The survival period is expected to be more than 3 months; 5. The main organ function is normal, which meets the following criteria: blood routine examination standard should be consistent with (14 days without using blood transfusion and blood products, no g-csf and other hematopoietic stimulation factor): (1) Hb 90 g/L or higher; (2) the ANC = 1.5 x 10^9 / L; (3) PLT = 80 x 10^9/L; biochemical tests shall meet the following criteria: (1) TBIL < 1.5 by ULN; (2) ALTAST < 2.5 x ULN; (3) BUN and Cr = 1 x ULN or endogenous creatinine clearance was greater than 50ml/min (Cockcroft -Gault formula); 6. No contraindication for hyperbaric oxygenation therapy; 7. Women should accept the pregnancy test (serum) in 7 days before recruiting into group, and the results must be negative.patients must be use the appropriate methods to prevent pregnancy during the trial and 8 weeks after the last gives the experimental drug; 8. The subjects volunteered to participate in this study, sign informed consent, obey the rules and follow-up

Exclusion criteria

Exclusion criteria: 1. Patients had undergone chemotherapy and radiotherapy for glioblastoma; 2. Patients who have high blood pressure and have been treated with antihypertensive drugs cannot be reduced to normal range (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg); 3. Always suffer from severe cardiovascular disease: II magnitude of myocardial ischemia and myocardial infarction, poor control of cardiac arrhythmias (including QTc interphase 440 ms or higher); 4. Abnormal coagulation function (INR > 1.5, APTT> 1.5uln), with bleeding tendency; 5. Multiple factors that affect oral drugs (such as chronic diarrhea and intestinal obstruction); 6. Patients suffering from uneasily controlled epilepsy; 7. Have contraindication for hyperbaric oxygenation therapy, such as pneumothoraxpulmonary bullauncontroled internal hemorrhage, cavitary pulmonary tuberculosis along with hemoptysis, rhinitis, nasal polyps, eustachian tube obstructionand so on; 8. Person with severe uncontrolled repeated infection or other serious uncontrolled accompanying disease; 9. Pregnant or lactating women; 10. Patients was considered not suitable by researchers in this trial.

Design outcomes

Primary

MeasureTime frame
OS;PFS;

Secondary

MeasureTime frame
Toxicities;ORR;

Countries

China

Contacts

Public ContactJiang Wei

Tianjin Huanhu Hospital

ro7jiang@163.com+86 13072201699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026